Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tempus AI, Inc.

Get SEC filing alerts via email and in your feed for Tempus AI, Inc.

TEM

Tempus AI, Inc.

About Tempus AI, Inc.

Tempus AI is a healthcare technology company specializing in precision medicine through Intelligent Diagnostics. It combines AI, genomic, clinical, and imaging data to develop personalized, accurate laboratory tests across oncology, neuropsychiatry, cardiology, and infectious diseases. Its platform integrates vast multimodal datasets, enabling data-driven therapy decisions, clinical trial matching, and drug discovery, serving healthcare providers, researchers, and life sciences companies worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tempus AI, Inc.

1
1
Tempus AI, Inc. Tempus AI Reports 36% Revenue Growth to $348.1 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Tempus AI, Inc. Tempus AI Reports $1.272 Billion Revenue for 2025, Driven by Diagnostics Growth

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Tempus AI, Inc. Tempus AI Reports 85% Revenue Growth to $334.2 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tempus AI, Inc. Tempus AI Reports 90% Revenue Growth to $314.6 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tempus AI, Inc. Tempus AI Reports 75% Revenue Growth to $255.7 Million, Net Loss Increases to $68 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tempus AI, Inc. Tempus AI Reports 33% Revenue Growth, Widened Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments